Synthesis of 6-Substituted pyridazine and pyridazinone derivatives as potential anti-inflammatory agents / (Record no. 177053)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06078namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20260111130042.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251226s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.19 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.19 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.04.M.Sc.2025.Ba.S |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Basma Ahmad Mohammad Ahmad Fateh, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Synthesis of 6-Substituted pyridazine and pyridazinone derivatives as potential anti-inflammatory agents / |
| Statement of responsibility, etc. | by Basma Ahmad Mohammad Ahmad Fateh ; Supervision Prof. Dr. Nadia Abdalla Khalil, Prof. Dr. Eman Mohamed Ahmed, Prof. Dr. Soha Hussein Emam. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | تشييد مشتقات من 6-مستبدلات البيريدازين والبيريدازينون ذات تأثير محتمل كمضادات للالتهاب |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 159 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 138-159. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | This thesis comprises four principal chapters. The first chapter is an <br/>introduction covering a brief literature survey on the synthesis of pyridazine and <br/>pyridazinone compounds in addition to a summary of the concept of inflammation, <br/>inflammatory response and different inflammatory mediators, especially TxA2, <br/>TNF-α and IL-6. It also includes a hint to the role of COX enzymes in the <br/>pathogenesis of inflammation and the variant anti-inflammatory agents. In addition, <br/>the potential role of the pyridazine and pyridazinone compounds in dealing with <br/>COVID-19 symptoms was discussed as well as narration of different pyridazine and <br/>pyridazinone derivatives acting as anti-inflammatory agents through inhibition of <br/>TxA2, TNF-α and IL-6. The second chapter sheds light on the work objectives, the <br/>rational design of the target compounds and the schemes used for the preparation of <br/>these compounds. The third chapter focuses on the theoretical discussion of <br/>experimental work as well as discussion of the biological activity of the newly <br/>synthesized compounds, in addition to molecular modeling studies and the structure-<br/>activity relationship. The fourth chapter represents the experimental part of the <br/>thesis containing the detailed procedures followed for the synthesis of the target <br/>compounds and their intermediates. Also, the physical characters and structure <br/>validation of the newly synthesized compounds through elemental analyses and <br/>spectral data were recorded. Moreover, this section explains the methodology of in <br/>vitro inhibition assays for five inflammatory biomarkers including COX-1, COX-2, <br/>TxA2, TNF-α and IL-6, in addition to steps of molecular docking. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | تحتوى الرسالة على أربعة فصول أساسية<br/>الفصل الأول، وهوعبارة عن مقدمة مختصرة عن:<br/>•الطرق المختلفة المستخدمة في تشييد بعض مشتقات البيريدازين و البيريدازينون.<br/>•الالتهابات واستجابة الجسم للالتهابات وكذلك وسائط الالتهاب المختلفة خصيصاًTxA2، TNF-α و IL-6.<br/>•دورإنزيمات سيكلواكسيجينيز في إحداث الالتهاب و الأدوية المتاحة المضادة للالتهاب.<br/>•مناقشة الدورالمحتمل لمشتقات البيريدازين و البيريدازينون في التعامل مع الأعراض المصاحبة لعدوى كوفيد-19.<br/>•نشاط بعض مشتقات البيريدازين و البيريدازينون كمضاداتللالتهاب و تأثيرها علىTxA2،TNF-α و IL-6.<br/>الفصل الثاني، يوضح الهدف من الرسالة وعرضالأسسالعلميةالتيبُنى عليهاتصميمالمركبات المستهدفة وعرض الخطط التي توضح الطرق العملية التى صُممت للحصول علي هذه المركبات.<br/>الفصل الثالث، يحتوي على المناقشة النظرية لكلٍ من الجزء العملي ونتائج التقييم الحيوية للمركبات المشيدة حديثاً ونتائج الإرساء الجزيئى، بالأضافة لدراسة العلاقة بين تركيب المركبات ومدى فاعليتها. <br/>الفصل الرابع، يعرض الإجراءات العملية المتبعة لتشييد المركبات المستهدفة والمركبات الوسيطة. بالإضافة إلى الخصائص الفيزيائية وتحاليل العناصر والتحاليل الطيفية للمركبات المشيدة. وأيضاً يوضح هذا الجزء الخطوات المتبعة للفحص المخبرى لقدرة جميع المركبات الجديدة علي تثبيط خمسة من العلامات الحيوية الالتهابية مثل إنزيم سيكلواكسيجينيز 1و2،TxA2، TNF-α وكذلك IL-6بالإضافةإلى الخطوات المتبعة فى الإرساءالجزيئي لهذه المركبات |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical chemistry |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الكيمياء الصيدلانية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Pyridazines |
| -- | Pyridazinones |
| -- | Anti-inflammatory |
| -- | COX-2 |
| -- | TxA2 |
| -- | TNF-α |
| -- | IL-6 |
| -- | بيريدازينون |
| -- | بيريدازين؛ |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nadia Abdalla Khalil |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Eman Mohamed Ahmed |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Soha Hussein Emam |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Nadia Abdalla Khalil |
| -- | Eman Mohamed Ahmed |
| -- | Soha Hussein Emam |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutical Organic Chemistry |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | قاعة الرسائل الجامعية - الدور الاول | قاعة الرسائل الجامعية - الدور الاول | 26.12.2025 | 92939 | Cai01.08.04.M.Sc.2025.Ba.S | 01010110092939000 | 26.12.2025 | 26.12.2025 | Thesis |